Talus Bio
Facts
- HQ
- Seattle, Washington, USA
- Sectors
- Biotechnology, Drug discovery, Life sciences
- Founded
- 2021 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Talus Bioscience Inc Seattle business license
- Stage
- startup
- Total raised
- $9.4M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $9.4M · Jul 2024 SEC Form D
- Founders
- Alex Federation, Lindsay Pino
Milad Alucozai spotlights Talus Bio's Ptarmigan-1: a 256-dimensional lookup model that screens trillions of compounds across the regulome and outperforms docking on STAT6 and KRAS G12C
Milad Alucozai describes Talus Bio's Ptarmigan-1, a model that maps proteins and small molecules into a shared 256-dimensional space to enable very fast, large-scale virtual screening across the human regulome without relying on static structures, and reports strong validation on STAT6 and KRAS G12C that suggest the model learned biological signals rather than memorizing data.
Plug and Play Seattle selects 11 startups for 12-week Batch 4, including Tokyo’s Aeterlink; demo day Dec. 3
Plug and Play Seattle selected 11 startups for its fourth 12-week accelerator cohort—10 from Seattle and one from Tokyo—working on technologies from space robotics and data-center optical links to wireless power and antibody therapeutics, with the program running through mid-December and a demo day on Dec. 3 at the Boeing Future of Flight.
Seattle Biotechs Including Archon and Cyrus Highlight AI's Promise and Pitfalls in Drug Development at 2025 Conference
Seattle biotech leaders at a 2025 conference acknowledged AI's significant potential in drug development while cautioning against overhype. Companies like Archon Biosciences and Cyrus Biotechnology are applying AI to innovate protein design and drug immunogenicity.
Talus Bioscience Raises $11.2M to Develop Drugs Targeting Undruggable Gene-Regulating Proteins
Seattle biotech Talus Bioscience raised $11.2 million in venture capital to advance its drug discovery platform targeting undruggable gene-regulating proteins linked to diseases. Founded in 2020 by Alex Federation and Lindsay Pino, Talus uses its MARMOT platform and machine learning to study transcription factors within living cells.
Talus Bioscience Secures $4.3M in Grants to Advance Gene Activity Drug Discovery Platform
Seattle-based biotech startup Talus Bioscience secured $4.3 million in non-dilutive grants from the Andy Hill Cancer Research Endowment and the SBIR program to advance its drug discovery platform targeting gene activity through transcription factors. The startup, led by CEO Alex Federation and CTO Lindsay Pino, has raised a total of $7 million in venture funding and $7.3 million in grants since its founding in 2020.
Phase Genomics Secures $2.5M to Develop AI Platform for Detecting Cancer Chromosomal Aberrations
Seattle startup Phase Genomics received $2.5 million in funding, including $2 million from the U.S. National Cancer Institute and $500,000 from Washington state's Andy Hill CARE Fund, to advance its AI-driven platform that detects chromosomal aberrations in cancer. The funding supports projects analyzing tumor samples to develop predictive scores for cancers like acute myeloid leukemia and colorectal cancer.
People
-
Alex Federation Founder, Co-Founder, CEO, Executive Officer, Director, Promoter
